Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23425

    +

    P2.07-050 - Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors (ID 10286)

    09:30 - 09:30  |  Presenting Author(s): Neil J Shah
    • Abstract

    Background:
    Checkpoint inhibitors targeting PD-1 and PD-L1 have emerged as the standard of care for patients with NSCLC. While generally well tolerated, immune related adverse events (irAEs) are a known complication and when serious, may require use of systemic corticosteroids. The impact of steroid use on checkpoint inhibitor efficacy remains unclear. Previous data suggest comparable response rates among patients who require steroids and those who do not. Here, we seek to confirm those findings and explore the impact of systemic steroids for irAEs on time to treatment failure (TTF) in patients with NSCLC.
    
    Method:
    Retrospective analysis was performed on all patients with advanced NSCLC at five institutions who received a checkpoint inhibitor (anti-PD-1 or anti-PD-L1 antibody) between January 1, 2011 and April 1, 2017. TTF was defined as the time from initiating therapy to start of a new therapy, last day of follow up or death. Development of any irAE and use of systemic corticosteroids was noted and median TTF and RR were compared between subgroups.
    
    Result:
    We identified 141 eligible patients with NSCLC treated with checkpoint inhibitors. Nineteen patients were excluded from the final analysis due to lack of any follow up or receipt of investigational agents or combinations. For the 122 evaluable patients, median TTF and RR were 169 days and 18%. A total of 30 (25%) patients developed any irAEs with median TTF and RR of 497 days and 32%. A total of 11 (9%) patients received systemic corticosteroids for irAEs. Among the patients who received steroids for irAEs, the median TTF and RR were 502 days and 27%. Our observation failed to demonstrate a statistically significant difference in median TTF among patients who received steroids and those who did not (p=0.4155).
    
    Conclusion:
    These retrospective data do not demonstrate a difference in response or treatment failure among patients who received steroids for irAEs and support the use of steroids when necessary.